Clinical Trial: NCT03170206
Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Dana-Farber Cancer Institute |
| Information Provided By: | Dana-Farber Cancer Institute |
| Last Update Posted: | 2026-02-12 |
Study Overview
Brief Summary
This trial is being conducted as a possible treatment for lung cancer with a specific change in the KRAS gene.
The drugs involved in this study are:
- Palbociclib
- Binimetinib
Official Title
Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Conditions
Lung Cancer
Intervention / Treatment
- Drug: Binimetinib
- Drug: Palbociclib
Other Study ID Numbers
- 16-531
Start Date (Actual)
2017-05-31
Primary Completion Date (Actual)
2023-02-28
Study Completion Date (Actual)
2025-12-31
Enrollment (Actual)
34
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Dana-Farber Cancer Institute |
| Information Provided By: | Dana-Farber Cancer Institute |
| Last Update Posted: | 2026-02-12 |
Study Overview
Brief Summary
This trial is being conducted as a possible treatment for lung cancer with a specific change in the KRAS gene.
The drugs involved in this study are:
- Palbociclib
- Binimetinib
Official Title
Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Conditions
Lung Cancer
Intervention / Treatment
- Drug: Binimetinib
- Drug: Palbociclib
Other Study ID Numbers
- 16-531
Start Date (Actual)
2017-05-31
Primary Completion Date (Actual)
2023-02-28
Study Completion Date (Actual)
2025-12-31
Enrollment (Actual)
34
Study Type
Interventional
Phase
Phase 1